AHD-BIZ-002 — Capital Plan v0.1
Avina Home Detox LLC Status: DRAFT v0.1 (built on the Avina Wellness umbrella Capital Plan, item 7 expanded) Date: 24/04/2026
1. The Thesis (one paragraph)
Avina Home Detox is the flagship clinical product. It incorporates IV therapy as integrated treatment alongside detoxification (per directive 24/04). $100,000 of founding capital launches the business. The model is family-clinical-bench at the top (Kelly CEO, Elizabeth CMO, sister LMFT, all founders aligned by equity), 1099 contractor at the bottom (every nurse, every IV practitioner, every consulting clinician). Fixed payroll near zero. Revenue is bundled per case. Profitable from Q3.
2. The $100,000 Capital Deployment
| Bucket | USD | Status |
|---|---|---|
| LLC formation + S-Corp election + Operating Agreement | $5,500 | Counsel-led |
| State licensure prep CA + NY + FL (applications + counsel time) | $25,000 | Counsel-led, Y1 |
| Malpractice E&O $5M/$10M Y1 premium | $12,000 | Bound Day 30 |
| Healthcare regulatory counsel retainer Y1 | $25,000 | Block-fee with Nelson Hardiman recommended |
| HIPAA-eligible EMR + encrypted vault + BAA + comms stack | $8,000 | Day 7 setup |
| DEA registration + state controlled-substance permits | $1,500 | Day 14 |
| General liability + cyber + commercial auto Y1 | $4,000 | Bound Day 30 |
| Brand finalisation (sub-brand wordmark, photography commission, website assets) | $8,000 | Day 30 |
| Founders’ working capital — Kelly $5K/mo + Elizabeth $3K/mo × 3 months | $24,000 | Reserved Day 1 |
| Family-office mailing campaign — 50 hand-delivered packs Q1+Q2 | $6,000 | Q2 fire |
| Software stack (CRM, accounting, scheduling, payroll) | $1,500 | Day 7 |
| Reserve | $-500 | (overrun) |
| TOTAL | $120,500 | Variance: -$20,500 |
Variance analysis: The Capital Plan v0.1 runs $20,500 over the original $100K budget per refined counsel and licensure scope. Resolution path: Defer the brand commission to Month 4 (revenue-funded) and reduce the family-office mailing to 25 packs Q1, deferring 25 to Q2. New net: $103,500. The remaining $3,500 is funded from Q1 revenue.
3. The Revenue Model — Pricing Architecture (item 7 expanded)
3.1 Three Engagement Tiers
| Tier | Description | Duration | Fee (USD) |
|---|---|---|---|
| Tier 1 — Detox-Only | 5-day standard medical detox in residence with 24-hour nursing, MD oversight, comfort medications, oral repletion | 5 days | $18,000 - $25,000 |
| Tier 2 — Detox + IV Recovery Course | 5-day detox + 5-session NAD/IV course over the post-acute window (week 2 and 3); integrated protocol; one engagement | 14 days | $30,000 - $45,000 |
| Tier 3 — Detox + Maintenance Subscription | Tier 2 + ongoing IV maintenance (NAD monthly, glutathione monthly, methylated B-complex monthly, hydration on demand); 12-month minimum | 12 months | $30,000 onboarding + $4,000 - $6,000/month subscription |
3.2 High-Acuity / Custom Engagements
| Indication | Duration | Fee (USD) |
|---|---|---|
| Benzodiazepine taper (long, complex) | 14-21 days | $35,000 - $60,000 |
| Polysubstance (sequenced protocol, multiple clinicians) | 7-14 days | $30,000 - $55,000 |
| Geographic premium (outside CA/NY/FL, Aspen / Hamptons / yacht) | varies | base + $15,000 logistics |
| Security + companion overlay (high-profile principal) | varies | base + $20,000-$50,000 |
3.3 What Is and Is Not Included
Included in every Tier: physician approval, all detox medications, 24-hour nursing for 5 days, IV starts and supplies, comfort meds, oral repletion, two-way physician availability, family briefing rhythm, post-engagement clinical record handover.
Not included (billed separately): clinical equipment beyond standard nursing kit (e.g. cardiac monitor if indicated), security personnel beyond standard NDAs, transportation beyond local courier of pharmacy, any surgical or hospital-level intervention triggered by case escalation (insurance liability transfers to the receiving facility).
3.4 Avina Home Detox Pricing Doctrine
- Avina does not publish prices on the website.
- Avina does not discount.
- Avina explains the basis for the price on the first conversation.
- The fee is set at engagement letter; no surprises, no overruns billed without written authorisation.
- Insurance is not accepted; all engagements are private-pay. Documentation provided to families and family offices for out-of-network reimbursement at their discretion.
4. Year 1 Financial Forecast
4.1 Revenue Build
| Quarter | Tier 1 cases | Tier 2 cases | Tier 3 active | Avg case (T1+T2) | Subscription revenue | Total revenue |
|---|---|---|---|---|---|---|
| Q1 | 1 | 0 | 0 | $20,000 | $0 | $20,000 |
| Q2 | 2 | 1 | 0 | $24,000 | $0 | $72,000 |
| Q3 | 3 | 3 | 1 | $28,000 | $15,000 | $183,000 |
| Q4 | 4 | 5 | 2 | $30,000 | $36,000 | $306,000 |
| Y1 | 10 | 9 | 2 active by EOY | $27,500 | $51,000 | $581,000 |
4.2 Cost Structure
| Line | Y1 (USD) | % of revenue |
|---|---|---|
| Direct clinician cost (1099 nurses + IV practitioners + consulting MDs ~32%) | ($186,000) | 32% |
| Founders’ draw (Kelly $60K + Elizabeth $36K Y1 retainer) | ($96,000) | 17% |
| Director of Nursing (1099 retainer + per-case, hired Month 4) | ($90,000) | 15% |
| Compliance + insurance + counsel + licensure ongoing | ($80,000) | 14% |
| Software + EMR + infrastructure | ($14,000) | 2% |
| Marketing + brand + family-office outreach | ($16,000) | 3% |
| G&A (no physical office Y1; virtual) | ($20,000) | 3% |
| Total operating expense | ($502,000) | 86% |
| EBITDA Year 1 | $79,000 | 14% |
Cash position end of Y1: ~$135,000 (capital + EBITDA - Q1 working capital draw). The business is self-funding from Q3.
5. Three-Year Build
| Line | Y1 | Y2 | Y3 |
|---|---|---|---|
| Tier 1 cases | 10 | 30 | 60 |
| Tier 2 cases | 9 | 50 | 110 |
| Tier 3 active subscribers (EOY) | 2 | 12 | 28 |
| Avg case revenue | $27,500 | $32,000 | $35,000 |
| Subscription revenue | $51,000 | $396,000 | $1,008,000 |
| Revenue | $581,000 | $2,956,000 | $6,958,000 |
| Operating expense | ($502K) | ($2.07M) | ($4.45M) |
| EBITDA | $79K | $886K | $2.51M |
| Margin | 14% | 30% | 36% |
Y2 expansion: NY licensure approved (Q1). Director of Nursing converts to W-2. First Avina Home Detox marketing brand pack publicly distributed. Subscription book becomes meaningful recurring revenue.
Y3 expansion: FL licensure approved. Second Medical Director hired (clinical coverage redundancy). LA flagship by-appointment office opened.
6. Five-Year Horizon
| Line | Y4 | Y5 |
|---|---|---|
| Tier 1 + Tier 2 cases per year | 220 | 360 |
| Tier 3 active subscribers (EOY) | 60 | 120 |
| Geographic spread | CA + NY + FL + TX + London | Add Geneva + Singapore |
| Revenue | $13.5M | $24M |
| EBITDA (38%) | $5.1M | $9.1M |
Y5 enterprise value (8x EBITDA, concierge clinical multiple): ~$73M. Y5 enterprise value (12x for a high-recurring-subscription book): ~$110M.
7. Sensitivity Analysis
Down case (50% revenue plan)
- Y1 revenue: $290K
- Y1 EBITDA: ($55K) — small loss
- Cash at EOY: ~$45K — bridge financing or founder loan needed
- Action: Defer Director of Nursing hire to Month 9, reduce founders’ draw 50%, total: profitable at break-even
Stretch case (150% revenue plan)
- Y1 revenue: $870K
- Y1 EBITDA: $235K
- Cash at EOY: $290K
- Action: Hire DON Month 2, hire first salaried Chief of Staff Month 11, accelerate NY licensure
What breaks the model
- CA licensure delay past Day 90. Mitigation: operate Y1 cases under existing Avina Wellness LLC where legally permitted while AHD LLC licensure is pending; transfer the book post-approval.
- First clinical incident. Mitigation: conservative Y1 case selection, MD kill-switch authority, $5M/$10M malpractice, no novel cases first 12 months.
- Elizabeth bandwidth. Mitigation: Y1 retainer caps her at 30 hr/wk; back-up CMO identified by Q2 as Plan B.
- Nurse pool quality. Mitigation: in-house training, DON validation gate, no first deployment without supervision.
- EKRA exposure. Mitigation: never pay for referrals, document every relationship, EKRA-trained counsel review all referral structures.
8. Capital Asks Beyond the $100K
None planned. The model is structured to be self-funding from Q3 Y1 through Y2-3 expansion using retained earnings.
If outside capital becomes attractive Y3+ for accelerated geographic expansion: - $1M-$2M friend-and-family or strategic angel round, preferred equity, 10-15% target dilution, valuation ~$8-12M post-money - Use of proceeds: Y4 jurisdictions (London, Geneva), second salaried Medical Director, brand investment
Debt financing: Avoided in Y1-Y2. Considered Y3+ for working capital bridge if revenue acceleration outpaces collections.
9. Decisions for Kelly + Fabian
- Capital approval: $100,000 deployed per Section 2 (with $3,500 deferred to Q1 revenue per variance resolution)
- Pricing tier confirmation: The three-tier architecture above (Detox-only, Detox + IV Recovery Course, Detox + Maintenance Subscription)
- Founders’ draw: Kelly $5K/mo + Elizabeth $3K/mo Y1
- Equity allocation: 80/20 Avina Wellness LLC / Elizabeth (vested 4-year)
- First-case strategy: Use existing UHNW relationship (Forbes-family principal) for first paid case in Q1, or wait for first inbound from Q1 family-office mailing?
- Subscription launch: Q3 (per plan above), or earlier?
End of v0.1. Refresh when NEXUS competitive landscape and clinical evidence research returns; pricing tiers may shift up if benchmarks support a higher anchor.